Series of novel triterpenoid hybrids were designed and synthesized by introducing 2-aminobenzamide moiety at C28 position of triterpenoid derivatives. Thirteen new conjugates were thus successfully prepared and evaluated as cytotoxic agents, revealing an interesting anticancer activity in KB and HepG2 cancer cell lines.
The pharmacophore hybridization of bioactive natural and unnatural compounds is one of the most promising for the design of new molecules with pronounced biological activities [1] [2] [3] [4] . In the pursuit of potential new hit compounds, the selection of molecules with high biological activities for hybridization is occupying an important role. Thus, triterpenoids have been attracting considerable interest in the past few years vested to their broad range of biological and medicinal properties [5] [6] [7] [8] [9] [10] . Betulin, betulinic acid, and its derivatives (such as ursolic acid, oleanolic acid and other triterpenoids) ( Figure 1 ) have been reported to be effective against a variety of cancer cell lines [11] [12] [13] , as well as anti-inflammatory, antimalarial [14] [15] [16] , rendering this class of natural products suitable candidates for pharmacophore hybridization. Another privileged scaffolds concerns 2-aminobenzamide, which has been known as zinc binding group in the molecular structure of histone diacetylase (HDAC) inhibitors. The lead compound of this class is chidamide (CS055) (Figure 2 ) that has been approved by CFDA on 2015 for the treatment of peripheral T-cell lymphoma [17] . Other HDAC inhibitors, such as tacedinaline (CI994) [18] , entinostat (MS-275) [19] , mocetinostat (MGCD0103) [20] ( Figure  2 ) are presently undergoing different clinical trials for the treatment of different kinds of cancer. Based on broad-spectrum of biological activities, several 2-aminobenzamide derivatives have been recently designed and synthesized as anticancer agents [21, 22] .
Despite their high biological potential, the combination of triterpenoids and 1,2-diaminobenzamide into single molecules has been studied to a rather limited up to now. Considering the documented anticancer activity of triterpenoids and 2-aminobenzamide, it is reasonable to suggest that the construction of novel triterpenoid derived 2-aminobenzamides might result in the identification of useful anticancer hits for further elaboration. Thus, in present work, series of novel triterpenoid hybrids were designed and synthesized by introducing 2-aminobenzamide moiety at C28 position of triterpenoid derivatives. The synthesized compounds were screened for their in vitro cytotoxicity against two human cancer cell lines (KB and HepG2). For this purpose, the conjugates of betulin derivatives with 1,2-diaminobenzene 3a-e were synthesized following the synthetic procedure illustrated in Scheme 1. The key intermediates 28-Oacylbetulins 2a-e were readily prepared by treament of acid anhydrides with betulin 1 in dichloromethane in the presence of triethylamine at room temperature for 24 h [23] . Compounds 2a-e were then used for the conjugation with 1,2-diaminobenzene in DMF in the presence of 1 equiv BOP, 2 equiv DMAP and 1.2 equiv Et 3 N at room temperature for 15 h to give the corresponding conjugates 3a-e. derivatization. Initial Jones oxidation (CrO 3 ) of β-hydroxy acids 4a,b using H 2 SO 4 in acetone resulted in the corresponding β-oxo acid intermediates, which was subjected to decarboxylation to provide ketones 5a,b. Reduction of compound 5a using sodium tetrahydroborate afforded compound 7, which was acetylated by acetic anhydride to give 3-acetylate derivative 8. Conjugation of compounds 5b, 8 with 1,2-diaminobenzene gave the corresponding conjugates 6 and 9, respectively. The conjugate 9 was then hydrolyzed using LiOH in methanol to afford the target compound 10 (Scheme 2). Furthermore, betulinic acid 11 was also employing as a substrate for hybridization with 1,2-diaminobenzene, affording conjugate 12 in a good yield (Scheme 3). Similarly, ketone 13, prepared from betulinic acid 11 [25] , was treated with 1,2-diaminobenzene at the same reaction conditions to afford compound 14 in 61% yield (Scheme 3).
Finally, ursolic acid 15 was acetyled to give compound 16, which was then reacted with 1,2-diaminobenzene in the presence of mixture BOP/DMAP/Et 3 N in dimethylformamide at room temperature for 15 h to furnish corresponding conjugate 17 (Scheme 4). Also compound 18, prepared form betulin [26] , was converted to In the next part of this work, the newly prepared compounds were subjected to cytotoxic evaluation in order to assess their biological relevance. Thus, triterpenoid derived 2-aminobenzamides 3a-e, 6, 9, 10, 12, 14, 17, 19, and 20 were evaluated in vitro for their cytotoxic activity against two human tumor cell lines (KB, HepG2), and the results are summarized in Table 1 . The results indicate that most of these derivatives possess at least moderate cytotoxic activity. In particular, compound 12 show good cytotoxicity against both cell lines KB and HepG2 with the IC 50 values of 12.1 µM and 15.1 µM, respectively, pointing to the potential interest in this new class of hybrid molecules. On the other hand, comparing to the cytotoxicity of 3-acetylate conjugates with the 3-hydroxy counterparts, it is clear that the acetylate analogs (9 and 19) exhibit more potent cytotoxic effects than corresponding hydroxyl counterparts (10 and 20).
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In conclusion, 13 new triterpenoid derived 2-aminobenzamides were successfully prepared and evaluated cytotoxic activity against two human cancer cell lines. The results indicate that most of these derivatives possess at least moderate cytotoxic activity.
Experimental
General: All reactions were performed in the appropriate ovendried glass apparatus and under atmospheric pressure. Unless otherwise stated, solvents and chemicals were obtained from commercial sources and used without further purification. Column chromatography was performed using silica gel (60Å, particle size 40-60 µm). NMR spectra were recorded on a Bruker Avance (500 MHz). Chemical shifts (δ) are given in parts per million (ppm) and coupling constants (J) in hertz (Hz 1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a] chrysen3a-yl)methyl 5- ((2-aminophenyl) ((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-((2-aminophenyl) 1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a- 1R,3aS,5aR ,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]  chrysen-3a-yl)methyl-6-((2-aminophenyl) (1R,3aS,5aR,5bR,8R,11aS)-N-(2-aminophenyl)-5a,5b,8,11a-tetramethyl-9,12-dioxo-1-(prop-1-en-2-yl) (1R,3aS,5aR,5bR,8R,9S,11aS)-3a-((2-aminophenyl)carbamoyl)-5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl) 1R,3aS,5aR,5bR,9S,11aR)-N-(2-aminophenyl)-9-hydroxy5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl) (1R,3aS,5aR,5bR,11aR)-N-(2-aminophenyl)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl) (3S,6aR,6bS,8aS,11R,12S,14bR)-8a-((2-aminophenyl)carbamoyl)  -4,4,6a,6b,11,12,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,  10,11,12,12a,14,14a,14b- (3aR,5aR,5bR,9S,11aR)-3a-((2-aminophenyl)carbamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,  7 a , 8 , 9 , 1 0 , 1 1 , 1 1 a , 1 1 b , 1 2 , 1 3 , 1 3 a -o c t a d e c a h y d r o -2 Preparation of compounds 10 and 20: To the solution of corresponding compound 9 or 19 (0.7 mmol) in methanol (5ml) was added LiOH (3.5 mmol), and the mixture was stirred at room temperature for 12h. Upon completion, the solvent was removed in vacuo, and the residue was redissolved in EtOAC (20 mL) and washed with water (20 mL). The aqueous phase was extracted with EtOAc (20 ml x 3). Drying (Na 2 SO 4 ), filtration of the drying agent, and removal of the solvent in vacuo afforded targeted compound 10, and 20, respectively, which were further purified by means of column chromatography on silica gel using n-hexane/ethyl acetate (7 : 3). (3aR,5aR,5bR,9S,11aR)-N-(2-aminophenyl)-9-hydroxy-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,  8,9,10,11,11a,11b,12,13,13a-octadecahydro-3aH- Supplementary data: Experimental details and the characterization data associated with this article can be found in the online version.
